Organ-enriched proteomic age gaps

There is 1 paper on organ-enriched proteomic age gaps in aging research: 1 trial in people. The newest story, Nov 9, 2026: “Exenatide lowered protein-based age scores in people”.

Biomarker

1 paper studies it1 finding

1 new paper in 30 daysSee all 1 papers on organ-enriched proteomic age gaps

  • Human trial1

Interventions

1

Exenatide

downin humans1

1 study
  1. Exenatide decreases organ-enriched proteomic age gaps in humans (type 2 diabetes; compared with placebo) (6 organ clocks decreased; interaction p<0.05).

    “6 decreased with 12 months of therapy, including heart, pancreas, brain, artery, adipose and muscle”

    Human trialtype 2 diabetes; compared with placeboheart, pancreas, brain, artery, adipose tissue, and muscleonce-weekly12 monthsn = 3,973

    Exenatide lowered protein-based age scores in people

    AHA Scientific Sessions 2026 abstract

More on Exenatide

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 11 paper in 12 months
AHA Scientific Sessions 2026 Abstract

Exenatide lowered protein-based age scores in people

Over 12 months, exenatide lowered six organ-related age scores and limited a liver score’s rise compared with placebo in people with type 2 diabetes.Over 12 months, exenatide lowered six organ-related age scores and limited a liver score’s rise compared with placebo in people with type 2 diabetes.

Randomized trial · 3,973 peopleExenatide